RT Journal Article
SR Electronic
T1 Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)
JF BMJ Open Respiratory Research
JO BMJ Open Resp Res
FD British Thoracic Society
SP e001049
DO 10.1136/bmjresp-2021-001049
VO 8
IS 1
A1 Jim M Wild
A1 Joanna C Porter
A1 Philip L Molyneaux
A1 Peter M George
A1 Iain Stewart
A1 Richard James Allen
A1 Raminder Aul
A1 John Kenneth Baillie
A1 Shaney L Barratt
A1 Paul Beirne
A1 Stephen M Bianchi
A1 John F Blaikley
A1 Jonathan Brooke
A1 Nazia Chaudhuri
A1 Guilhem Collier
A1 Emma K Denneny
A1 Annemarie Docherty
A1 Laura Fabbri
A1 Michael A Gibbons
A1 Fergus V Gleeson
A1 Bibek Gooptu
A1 Ian P Hall
A1 Neil A Hanley
A1 Melissa Heightman
A1 Toby E Hillman
A1 Simon R Johnson
A1 Mark G Jones
A1 Fasihul Khan
A1 Rod Lawson
A1 Puja Mehta
A1 Jane A Mitchell
A1 Manuela Platé
A1 Krisnah Poinasamy
A1 Jennifer K Quint
A1 Pilar Rivera-Ortega
A1 Malcolm Semple
A1 A John Simpson
A1 DJF Smith
A1 Mark Spears
A1 LIsa G Spencer
A1 Stefan C Stanel
A1 David R Thickett
A1 A A Roger Thompson
A1 Simon LF Walsh
A1 Nicholas D Weatherley
A1 Mark Everard Weeks
A1 Dan G Wootton
A1 Chris E Brightling
A1 Rachel C Chambers
A1 Ling-Pei Ho
A1 Joseph Jacob
A1 Karen Piper Hanley
A1 Louise V Wain
A1 R Gisli Jenkins
YR 2021
UL http://bmjopenrespres.bmj.com/content/8/1/e001049.abstract
AB Introduction The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD).Methods and analysis The UK Interstitial Lung Disease Consortium (UKILD) will undertake longitudinal observational studies of patients with suspected ILD following COVID-19. The primary objective is to determine ILD prevalence at 12 months following infection and whether clinically severe infection correlates with severity of ILD. Secondary objectives will determine the clinical, genetic, epigenetic and biochemical factors that determine the trajectory of recovery or progression of ILD. Data will be obtained through linkage to the Post-Hospitalisation COVID platform study and community studies. Additional substudies will conduct deep phenotyping. The Xenon MRI investigation of Alveolar dysfunction Substudy will conduct longitudinal xenon alveolar gas transfer and proton perfusion MRI. The POST COVID-19 interstitial lung DiseasE substudy will conduct clinically indicated bronchoalveolar lavage with matched whole blood sampling. Assessments include exploratory single cell RNA and lung microbiomics analysis, gene expression and epigenetic assessment.Ethics and dissemination All contributing studies have been granted appropriate ethical approvals. Results from this study will be disseminated through peer-reviewed journals.Conclusion This study will ensure the extent and consequences of LC-ILD are established and enable strategies to mitigate progression of LC-ILD.